OPSIDIO
A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .
OPSIDIO
Industry:
Biotechnology Medical
Founded:
2012-01-01
Address:
Bryn Mawr, Pennsylvania, United States
Country:
United States
Website Url:
http://www.opsidio.com
Status:
Active
Contact:
(484) 557-0698
Total Funding:
500 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network ReCAPTCHA GStatic Google Static Content Wix
Similar Organizations
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Current Employees Featured
Nicholas Lukacs Co-Founder & CSO @ Opsidio
Co-Founder & CSO
Martin Phillips Chief Executive Officer @ Opsidio
Chief Executive Officer
2013-01-01
Steven Kunkel Co-Founder & Advisor @ Opsidio
Co-Founder & Advisor
Founder
Investors List
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels investment in Venture Round - Opsidio
BioAdvance
BioAdvance investment in Venture Round - Opsidio
Official Site Inspections
http://www.opsidio.com
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Opsidio"
OPSIDIO
At OPSIDIO, we’re passionate about developing remedies for the millions of people affected by the damaging effects of chronic inflammation. Chronic inflammation stemming from diverse …See details»
Opsidio - Crunchbase Company Profile & Funding
Organization. Opsidio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Opsidio is a biotechnology company that …See details»
About Us - OPSIDIO
It was this discovery that led to the formation of Opsidio and the development of OpSCF. About Us: About Us. The Leadership Team. Martin Phillips, MD. CEO. Over 30 years experience in academic medicine, pharmaceutical and biotech …See details»
Opsidio Company Profile 2024: Valuation, Funding & Investors
Opsidio General Information Description. Developer of monoclonal antibodies designed to treat patients suffering from fibrotic and allergic diseases. The company's antibodies target the …See details»
Opsidio - Overview, News & Similar companies | ZoomInfo.com
Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis – OpSCF is a novel monoclonal antibody directed against the inflammatory form of …See details»
Opsidio, LLC - LinkedIn
Opsidio, LLC | 153 followers on LinkedIn. Opsidio, a preclinical stage biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases.See details»
Opsidio, LLC Overview | SignalHire Company Profile
Opsidio, LLC is a private company that has been in the industry for 11 years. The company currently specializes in the Biotechnology area. ... Organization Website. opsidio.com . …See details»
Opsidio - Products, Competitors, Financials, Employees, …
Opsidio is headquartered in Bryn Mawr, PA with additional facilities in Ann Arbor, MI. For further information, please contact Martin Phillips or Jim Jogerst, at info@opsidio.com About …See details»
Opsidio Company Profile - Office Locations, Competitors ... - Craft
Opsidio is a biotechnology company that develops biologic therapeutics to treat chronic inflammatory diseases. Its lead candidate, OpSCF, is aimed at interrupting chronic …See details»
OPSIDIO LLC - VentureRadar
Similar Companies: Aqualung Therapeutics USA Privately Held Aqualung Therapeutics is a biotech company developing a novel, anti-inflammatory monoclonal antibody strategy to treat …See details»
Opsidio - Crunchbase
Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. Search Crunchbase. Start Free Trial . Chrome …See details»
Opsidio LLC Company Profile | Bryn Mawr, PA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Opsidio LLC of Bryn Mawr, PA. Get the latest business insights from Dun & Bradstreet.See details»
Opsidio - Funding, Financials, Valuation & Investors - Crunchbase
Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. Search Crunchbase. ... How much funding has …See details»
Opsidio LLC - Drug pipelines, Patents, Clinical trials - Synapse
6 days ago Explore Opsidio LLC with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 2 news, Disease Domain:Immune System Diseases, Technology …See details»
Opsidio.com’s Competitors, Revenue, Number of Employees
Opsidio.com’s Profile, Revenue and Employees. Opsidio is a biotechnology company that develops therapeutics for glomerulonephritis, pulmonary fibrosis, and scleroderma diseases.See details»
Opsidio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Opsidio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Contacts 2. ... Opsidio …See details»
Our Science - OPSIDIO
Opsidio has designed a monoclonal antibody (OpSCF) that specifically targets the SCF248 isoform with high affinity. OpSCF does not bind to SCF220 or the soluble extracellular domain …See details»
Opsidio Stock Price, Funding, Valuation, Revenue & Financial …
Sep 25, 2017 Opsidio has raised $800K over 1 rounds. Opsidio's latest funding round was a Bridge for $0.8M on September 25, 2017. Date. Round. Amount. Investors. Valuation. …See details»
Opsidio - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. Search Crunchbase Start Free TrialSee details»
Opsidio began dosing the first patient in a Phase 2a trial of
Dec 8, 2023 Opsidio, LLC, a biotech organization actively engaged in the development of novel treatments aimed at addressing inflammation-related health conditions, has confirmed …See details»